Loading...

Denali Therapeutics

Nasdaq:DNLI
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DNLI
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Denali Therapeutics has significant price volatility in the past 3 months.
DNLI Share Price and Events
7 Day Returns
0%
NasdaqGS:DNLI
0.3%
US Biotechs
-1.4%
US Market
1 Year Returns
4%
NasdaqGS:DNLI
-4.9%
US Biotechs
1.6%
US Market
DNLI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Denali Therapeutics (DNLI) 0% -16.1% -5.9% 4% - -
US Biotechs 0.3% -1.4% -4.9% -4.9% 3.6% 11%
US Market -1.4% -3.9% 0.2% 1.6% 33.2% 38.2%
1 Year Return vs Industry and Market
  • DNLI outperformed the Biotechs industry which returned -4.9% over the past year.
  • DNLI outperformed the Market in United States of America which returned 1.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Denali Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Denali Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $20.73.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Denali Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Denali Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:DNLI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.55
NasdaqGS:DNLI Share Price ** NasdaqGS (2019-05-24) in USD $20.73
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 18.23x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 17.44x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Denali Therapeutics.

NasdaqGS:DNLI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:DNLI Share Price ÷ EPS (both in USD)

= 20.73 ÷ -0.55

-37.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Denali Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Denali Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Denali Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGS:DNLI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -37.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-8.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.22x
United States of America Market PEG Ratio Median Figure of 2,121 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Denali Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Denali Therapeutics's assets?
Raw Data
NasdaqGS:DNLI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $5.42
NasdaqGS:DNLI Share Price * NasdaqGS (2019-05-24) in USD $20.73
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.17x
United States of America Market PB Ratio Median Figure of 5,207 Publicly-Listed Companies 1.8x
NasdaqGS:DNLI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:DNLI Share Price ÷ Book Value per Share (both in USD)

= 20.73 ÷ 5.42

3.82x

* Primary Listing of Denali Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Denali Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Denali Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Denali Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Denali Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-8.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Denali Therapeutics expected to grow at an attractive rate?
  • Unable to compare Denali Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Denali Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Denali Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:DNLI Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:DNLI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -8.7%
NasdaqGS:DNLI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 20.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:DNLI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:DNLI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 295 -123 -125 1
2022-12-31 133 -239 -194 1
2021-12-31 116 -197 -188 2
2020-12-31 146 -114 -146 3
2019-12-31 78 -90 -132 4
NasdaqGS:DNLI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 133 -14 -52
2018-12-31 129 50 -36
2018-09-30 3 -61 -137
2018-06-30 2 -49 -123
2018-03-31 1 -24 -91
2017-12-31 -77 -88
2017-09-30 -77 -85
2017-06-30 -76 -93
2017-03-31 -75 -90
2016-12-31 -72 -87

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Denali Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Denali Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:DNLI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Denali Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:DNLI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.19 -0.20 -2.17 2.00
2022-12-31 -1.81 -1.45 -2.17 2.00
2021-12-31 -1.70 -1.14 -2.02 3.00
2020-12-31 -1.59 -0.96 -2.25 5.00
2019-12-31 -1.48 -0.73 -1.95 5.00
NasdaqGS:DNLI Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.55
2018-12-31 -0.39
2018-09-30 -1.78
2018-06-30 -2.20
2018-03-31 -2.58
2017-12-31 -5.89
2017-09-30 -9.16
2017-06-30 -11.15
2017-03-31 -12.24
2016-12-31 -13.49

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Denali Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Denali Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Denali Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Denali Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Denali Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Denali Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Denali Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Denali Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Denali Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Denali Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:DNLI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 132.72 -51.55 36.09
2018-12-31 129.16 -36.24 32.35
2018-09-30 3.48 -136.66 26.37 74.46
2018-06-30 2.29 -123.13 21.31 74.46
2018-03-31 0.64 -90.54 17.98
2017-12-31 -88.19 15.68
2017-09-30 -84.65 13.66 16.75
2017-06-30 -93.42 13.00 39.27
2017-03-31 -89.63 12.22 54.85
2016-12-31 -86.65 11.73
2015-12-31 -16.79 5.11 10.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Denali Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Denali Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Denali Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Denali Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Denali Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Denali Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Denali Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Denali Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Denali Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Denali Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Denali Therapeutics Company Filings, last reported 1 month ago.

NasdaqGS:DNLI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 516.65 71.41 485.48
2018-12-31 546.85 0.00 464.30
2018-09-30 461.18 0.00 374.96
2018-06-30 490.27 0.00 372.59
2018-03-31 539.03 0.00 373.40
2017-12-31 465.80 0.00 406.23
2017-09-30 193.14 0.00 185.80
2017-06-30 213.32 0.00 186.96
2017-03-31 254.52 0.00 178.33
2016-12-31 254.52 0.00 178.33
2015-12-31 32.67 0.00 30.74
  • Denali Therapeutics's level of debt (13.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Denali Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Denali Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Denali Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -66.1% each year.
X
Financial health checks
We assess Denali Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Denali Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Denali Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Denali Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Denali Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Denali Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Denali Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:DNLI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2007 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:DNLI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Denali Therapeutics has not reported any payouts.
  • Unable to verify if Denali Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Denali Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Denali Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Denali Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Denali Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Denali Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Denali Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Denali Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ryan Watts
COMPENSATION $5,983,923
AGE 42
TENURE AS CEO 3.8 years
CEO Bio

Dr. Ryan J. Watts, Ph.D. is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since August 2015. Dr. Watts has been a Director of Denali Therapeutics Inc. since March 2015. From March 2015 to August 2015, Dr. Watts acted as interim President, Chief Scientific Officer and Head of Research and Development of Denali Therapeutics Inc. Dr. Watts served as Director of the Department of Neuroscience at Genentech, where he was employed for 11 years. During his tenure, he led Genetech entry into neuroscience, building a department and advancing multiple programs for neurological disease from discovery to clinical testing. His own laboratory focused on understanding mechanisms of neurodegeneration and on drug discovery for Alzheimer’s disease. He is also a leader in the development of improved methods for delivering therapeutic antibodies across the blood-brain barrier. He obtained his B.S. from the University of Utah and his Ph.D. in biological sciences from Stanford University.

CEO Compensation
  • Ryan's compensation has increased whilst company is loss making.
  • Ryan's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Denali Therapeutics management team in years:

3.6
Average Tenure
45
Average Age
  • The tenure for the Denali Therapeutics management team is about average.
Management Team

Ryan Watts

TITLE
Co-Founder
COMPENSATION
$6M
AGE
42
TENURE
3.8 yrs

Alex Schuth

TITLE
Co-Founder
COMPENSATION
$4M
AGE
45

Marc Tessier-Lavigne

TITLE
Co-Founder
COMPENSATION
$405K
AGE
58

Steve Krognes

TITLE
CFO & Treasurer
COMPENSATION
$4M
AGE
50
TENURE
3.6 yrs

Carole Ho

TITLE
Chief Medical Officer & Head of Development
COMPENSATION
$4M
AGE
45
TENURE
3.9 yrs

Dana Andersen

TITLE
Chief Technical and Manufacturing Officer
TENURE
0.8 yrs

Chris Walsh

TITLE
Vice President of Legal
TENURE
0.3 yrs

Cindy Dunkle

TITLE
Head of Human Resources

Joe Lewcock

TITLE
Head of Biology Discovery

Zach Sweeney

TITLE
Head of Discovery
Board of Directors Tenure

Average tenure and age of the Denali Therapeutics board of directors in years:

4
Average Tenure
58
Average Age
  • The tenure for the Denali Therapeutics board of directors is about average.
Board of Directors

Vicki Sato

TITLE
Chairperson
COMPENSATION
$428K
AGE
69
TENURE
2.8 yrs

Ryan Watts

TITLE
Co-Founder
COMPENSATION
$6M
AGE
42
TENURE
4.2 yrs

Marc Tessier-Lavigne

TITLE
Co-Founder
COMPENSATION
$405K
AGE
58

Peter Klein

TITLE
Independent Director
COMPENSATION
$644K
AGE
56
TENURE
1.2 yrs

Doug Cole

TITLE
Director
COMPENSATION
$403K
AGE
58
TENURE
4 yrs

Jay Flatley

TITLE
Director
COMPENSATION
$404K
AGE
65
TENURE
4.1 yrs

Bob Nelsen

TITLE
Director
COMPENSATION
$384K
AGE
56
TENURE
4 yrs

David Schenkein

TITLE
Director
COMPENSATION
$404K
AGE
61
TENURE
4.1 yrs

Scott Biller

TITLE
Member of Scientific Advisory Board
AGE
62

Alison Goate

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Denali Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Denali Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?

Today we will look at DNLI’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis. … View our latest analysis for Denali Therapeutics

Simply Wall St -

Is Denali Therapeutics Inc's (NASDAQ:DNLI) Balance Sheet Strong Enough To Weather A Storm?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is DNLI growing fast enough to value financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

Denali Therapeutics Inc (NASDAQ:DNLI): Time For A Financial Health Check

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does DNLI's growth rate justify its decision for financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

What Should We Expect From Denali Therapeutics Inc's (NASDAQ:DNLI) Earnings Over The Next Few Years?

The latest earnings release Denali Therapeutics Inc's (NASDAQ:DNLI) announced in September 2017 showed that losses became smaller relative to the prrior year's level - great news for investors Below is my commentary, albeit very simple and high-level, on how market analysts perceive Denali Therapeutics's earnings growth outlook over the next couple of years and whether the future looks brighter. … NasdaqGS:DNLI Future Profit Jan 11th 18 Although it’s useful to understand the rate of growth each year relative to today’s figure, it may be more valuable evaluating the rate at which the company is growing on average every year. … Future Earnings: How does DNLI's growth rate compare to its peers and the wider market2

Simply Wall St -

What’s Ahead For Denali Therapeutics Inc (NASDAQ:DNLI)?

Check out our latest analysis for Denali Therapeutics What’s the catalyst for Denali Therapeutics's sector growth? … Denali Therapeutics recently delivered an industry-beating growth rate in earnings, which is a positive for shareholders. … However, if you’re relatively concentrated in biotech, you may want to value Denali Therapeutics based on its cash flows to determine if it is overpriced based on its current growth outlook.

Simply Wall St -

Company Info

Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson’s disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson’s disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer’s disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it is developing LF1, an undisclosed large molecule program to treat neurodegenerative diseases. Additionally, the company has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California.

Details
Name: Denali Therapeutics Inc.
DNLI
Exchange: NasdaqGS
Founded: 2013
$1,979,267,045
95,478,391
Website: http://www.denalitherapeutics.com
Address: Denali Therapeutics Inc.
161 Oyster Point Boulevard,
2nd Floor,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS DNLI Common Stock Nasdaq Global Select US USD 08. Dec 2017
DB 4DN Common Stock Deutsche Boerse AG DE EUR 08. Dec 2017
MUN 4DN Common Stock Boerse Muenchen DE EUR 08. Dec 2017
Number of employees
Current staff
Staff numbers
200
Denali Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/26 00:54
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/21
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.